Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2021-12-02 00:00:00 ET · period of report 2021-11-30 · accession 0001127602-21-030063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-02 | 2021-11-30 | BCRX | ASELAGE STEVE | Dir | A - Grant | $12.06 | +414 | 32.9K | +1% | +$4,993 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-30 | A | A | 414 | $12.06 | 32,858 | D | — | — | (F1) Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. |